Orudis, Oruvail, Ketoprofen News

Published Online: May 7, 2009 - 12:00:14 AM Manufacturers of OTC painkillers and fever reducers have 1 year to relabel all their products to include warnings about potential safety risks, such as liver damage and internal bleeding, according to a new FDA rule.

Many over-the-counter pain relievers will be required to carry stiffer warnings as the United States Food and Drug Administration implements its new labeling rules.

April 28, 2009 -- The FDA has implemented new rules requiring stronger and more extensive label warnings about the risk of liver damage and stomach bleeding for people taking common over-the-counter pain relievers.

The Food and Drug Administration issued a final rule that requires manufacturers of over-the-counter pain relievers and fever reducers to revise their labeling to include warnings about potential safety risks, such as internal bleeding and liver damage, associated with the use of these popular drugs.

IDEA reports results from a prospective 3 years phase III study of Diractin Munich, Germany April 2, 2009.